アフターアワーズ： 43.38 0.02 +0.05%

Bristol-Myers Squibb Co. (BMY)

Bristol-Myers Squibb Co. (BMY) 最新ニュース

Bristol-Myers Squibb Co. (BMY)

Bristol-Myers Squibb Co. (BMY) 最新ニュース

November 15th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq

Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion - MSN

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

BMS reports four-year data from psoriasis treatment extension trial - Clinical Trials Arena

BMS reports four-year data from psoriasis treatment extension trial - Clinical Trials Arena

Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch

Walmart Earnings & the State of the Consumer

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated F - Benzinga

Bristol Myers Squibb Enters Oversold Territory (BMY) - Nasdaq

BMY: 3 Pharma Stocks Primed for May Investment Opportunities - StockNews.com

FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma - Pharmaceutical Technology

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma - Pharmaceutical Technology

Our company - Worldwide locations - Bristol Myers Squibb

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed ... - Financial Times

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal - Yahoo Movies Canada

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Pfizer: Best Trading Momentum Since 2021 And 6% Yield

Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda ... - Chronicle-Tribune

Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda ... - Business Wire

Drug Tech Co. Hires J&J Atty As Chief Strategy Officer - Law360

Why Bristol Myers Squibb turned to Ted Danson to promote a plaque psoriasis treatment - PR Week

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch

Why Bristol Myers Squibb turned to Ted Danson to promote a plaque psoriasis treatment - PR Week

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC - Pharmaceutical Technology

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study - Yahoo Finance

Bristol Myers fails to beat AstraZeneca in stage 3 lung cancer - FiercePharma

Our company - Worldwide locations - Bristol Myers Squibb

Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0% - Defense World

Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know - Yahoo New Zealand News

Is Bristol Myers' Dividend in Danger? - The Motley Fool

Bristol Myers CEO Caforio to step down - Yahoo Movies Canada

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs - BenefitsPro

2 Beaten-Down Stocks to Buy and Hold for 10 Years

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields

Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs - BenefitsPro

BMYに似た銘柄